Markets are exploding higher on vaccine hopes.
Moderna Inc. (MRNA) took a hit in recent days after STAT News noted that some vaccine experts were skeptical of the MRNA data. In fact, they noted Moderna study did not provide critical information to assess effectiveness.
“The statnews.com report states that data from only eight patients out of total 45 and also only two weeks of data following the second dosage also raise concerns related to the durability of the data. Data on majority of p...
Already a member? Login below, or click here to register now for free.